Education
About Us
Working with TipRanks
Follow Us
Ardelyx (DE:41X)
FRANKFURT:41X
41X Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.15 - €8.57
Previous CloseN/A
Volume0.00
Average Volume (3M)496.00
Market Cap
$1.17B
Enterprise Value€1.54B
Total Cash (Recent Filing)$36.15M
Total Debt (Recent Filing)$104.93M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding238,356,220
10 Day Avg. Volume356
30 Day Avg. Volume496
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.79
Price to Cash Flow (P/CF)32.20
P/FCF Ratio32.20
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.44
Enterprise Value/Ebitda-92.12
Forecast
1Y Price Target
€10.08Price Target Upside107.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Earnings And Sales GrowthArdelyx reported a solid total revenue of ~$116.1M, demonstrating strong commercial execution as Ibsrela's expanded sales force gains traction.
Future Sales ProjectionsManagement reiterated their long-term combined peak sales guidance of $1.75B for Ibsrela and Xphozah, capturing new efforts to deepen Ibsrela's reach via omnichannel efforts and add additional access personnel.
Bears Say
Regulatory And Reimbursement ChallengesXPHOZAH is no longer available under Medicare Part D as of January 1, 2025, which limits favorable reimbursement for 60% of patients.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.69% Insiders
20.18% Mutual Funds
10.93% Other Institutional Investors
53.09% Public Companies and Individual Investors
41X FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was €4.15 and its highest was €8.57 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.17B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is May 01, 2025 which is in 51 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Feb 20, 2025. The company reported €0.019 earnings per share for the quarter, beating the consensus estimate of €0.004 by €0.015.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.1.
How many shares outstanding does Ardelyx have?
Ardelyx has 238,356,220 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of €0.019 in its last earnings report, beating expectations of €0.004. Following the earnings report the stock price went down -14.624%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in DE:41X
---
Ardelyx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.08 (107.31% Upside)
€10.08 (107.31% Upside)
Blogger Sentiment
Bullish
DE:41X Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.91%
12-Months-Change
Fundamentals
Return on Equity
-23.01%
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
41X Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.Read More>---
41X Stock 12 Month Forecast
Average Price Target
€10.08
▲(107.31% Upside)
Technical Analysis
Best Analysts Covering 41X
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+59.47%
reiterated a buy rating 4 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +59.47% per trade.
---